CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 40 enrolled
Drug / intervention
Nivolumab - 240 mg +6 moredrug
Likely dose
Nivolumab - 240 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02648997
NCT02648997Phase 2Active
CompareCT.gov

An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progressive/Recurrent Meningioma

Dana-Farber Cancer Institute·interventional·Posted Jan 7, 2016·Updated Jan 26, 2026

In Brief

A Phase 2 clinical trial evaluating Nivolumab - 240 mg, Ipilimumab - 1 mg/kg, and 5 other interventions for Meningiomas. Active but no longer recruiting, targeting 40 participants across 1 site.

Detailed Summary

This research study is studying targeted immunotherapies as a possible treatment for recurrent meningioma. The names of the study interventions involved in this study are nivolumab and ipilimumab.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeningiomas
CountriesUnited States
CollaboratorsBristol-Myers Squibb

Timeline

Phase 2ActiveOverdue
20162017201820192020202120222023202420252026
First PostedJan 7, 2016
Enrollment StartMar 1, 2016
Primary CompletionDec 1, 2024
Study CompletionJun 1, 2026
TodayJul 2, 2026
Enrollment to primary: 8.8 yearsPosted 10.5 years ago

Interventions

Nivolumab - 240 mgdrug

240 mg every 2 weeks

Ipilimumab - 1 mg/kgdrug

1 mg/kg every 3 weeks

Nivolumab - 480 mgdrug

480 mg once every 4 weeks

Nivolumab - 3 mg/kgdrug

3 mg/kg every 3 weeks

External Beam RTradiation

IMRT, 3D-CRT, or proton-beam radiation therapy

Nivolumab - 1 mg/kgdrug

1 mg/kg every 3 weeks

Ipilimumab - 3 mg/kgdrug

3 mg/kg every 3 weeks